Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Is Our Approach to Renal (Kidney) Cell Cancer Changing? 3 Important ESMO Studies

Is Our Approach to Renal (Kidney) Cell Cancer Changing? 3 Important ESMO Studies

The most common adult kidney cancer is renal cell carcinoma. Surgery is the primary treatment. No proven postoperative preventive option existed in early disease, while targeted treatments significantly extended advanced-disease survival.

At ESMO 2016, 3 important studies in this field were presented; let us examine them together:

Study-1

In disease spreading to other organs (metastatic) renal cell carcinoma, first-line sunitinib is our standard treatment. It inhibits intracellular growth and proliferation signaling called tyrosine kinase in the inner cell membrane. To determine whether new drugs could outperform this standard, researchers compared sunitinib with the targeted medicine cabozantinib , a multireceptor inhibitor also blocking receptors involved in tumor resistance.

This phase-II trial included metastatic (stage 4) patients, 80 in total. Cabozantinib outperformed Sunitinib, adding 3 months of disease control and yielding 30 months overall survival. These are the best survival results in stage 4 renal cell cancer. Promising but insufficient to change routine practice, they await larger phase-III results. Similar success there would substantially alter oncology practice.

Study 2

Another study tested postoperative prevention in early nonmetastatic kidney cancer. Previous research had proven no recurrence-reducing benefit after surgery, so we observe without additional treatment. The first of two studies asking aboutadjuvantbenefit showed that high-risk patients taking sunitinib for 1 year gained longer time after treatment before recurrence (at 5 years, an %8 benefit), compared with no treatment. Presented at the congress and simultaneously published in New England Journal of Medicine, the study continues follow-up, so overall survival results are not yet published.

Study 3

Despite that positive result, another early-stage postoperative study found no benefit from sunitinib or sorafenib.

Thus, one positive and one negative study address postoperative preventive chemotherapy. Overall survival analyses are needed before changing practice.

Conclusion

Though not yet standard, these three studies offer hope for better outcomes with new-generation treatments.

Sources

1. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial, presented by Dr Toni Choueiri during Presidential Symposium 3 on Monday, 10 October, 16:30 to 18:10 (CEST).
ESMO 2016, Abstract LBA30_PR.

2- Alain Ravaud, M.D., Ph.D., Robert J. Motzer, M.D., Hardev S. Pandha, M.D., Ph.D. et al.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
October 10, 2016DOI: 10.1056/NEJMoa1611406

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Is Our Approach to Renal (Kidney) Cell Cancer Changing? 3 Important ESMO Studies

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy